We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.01%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$111M
AUM Growth
+$2.3M
Cap. Flow
+$4.8M
Cap. Flow %
4.31%
Top 10 Hldgs %
45.14%
Holding
70
New
3
Increased
23
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$648K
2
UTHR icon
United Therapeutics
UTHR
+$525K
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$509K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$340K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$316K

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$613K
2
MYGN icon
Myriad Genetics
MYGN
+$527K
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$404K
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$220K
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$140K

Sector Composition

Rank Sector Weight
1 Healthcare 73.61%
2 Miscellaneous 26.05%
3 Real Estate 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QGEN icon
26
Qiagen
QGEN
$9.03B
$2.03M 1.82%
60,753
+7,191
+13% +$248K
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$12.6B
$1.85M 1.66%
19,926
+3,164
+19% +$280K
ALXN
28
DELISTED
Alexion Pharmaceuticals
ALXN
$1.61M 1.44%
11,447
+1,921
+20% +$261K
LABU icon
29
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$720M
$1.37M 1.23%
800
– –
LLY icon
30
CALL
Eli Lilly
LLY
$1.05T
$1.28M 1.15%
15,000
– –
LOXO
31
DELISTED
Loxo Oncology, Inc
LOXO
$1.27M 1.14%
13,800
– –
CLVS
32
DELISTED
Clovis Oncology, Inc.
CLVS
$1.24M 1.11%
15,000
– –
KPTI icon
33
Karyopharm Therapeutics
KPTI
$44M
$1.1M 0.99%
6,667
– –
PRTK
34
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1M 0.9%
40,000
– –
PCRX icon
35
Pacira BioSciences
PCRX
$1.03B
$939K 0.84%
25,000
– –
GILD icon
36
CALL
Gilead Sciences
GILD
$185B
$810K 0.73%
10,000
– –
AXSM icon
37
Axsome Therapeutics
AXSM
$10.8B
$741K 0.66%
133,500
– –
JUNO
38
DELISTED
Juno Therapeutics, Inc.
JUNO
$660K 0.59%
14,720
-3,250
-18% -$111K
TSRO
39
DELISTED
TESARO, Inc.
TSRO
$646K 0.58%
5,000
– –
ADMS
40
DELISTED
Adamas Pharmaceuticals
ADMS
$635K 0.57%
30,000
– –
RARE icon
41
Ultragenyx Pharmaceutical
RARE
$2.59B
$634K 0.57%
11,899
+5,742
+93% +$340K
BIVV
42
DELISTED
Bioverativ Inc. Common Stock
BIVV
$631K 0.57%
+11,056
New +$648K
NBIX icon
43
Neurocrine Biosciences
NBIX
$15.8B
$591K 0.53%
9,644
+4,469
+86% +$236K
ACAD icon
44
Acadia Pharmaceuticals
ACAD
$5.12B
$589K 0.53%
+15,639
New +$509K
GRFS
45
Grifois
GRFS
$5.32B
$543K 0.49%
24,805
+11,920
+93% +$247K
CRL icon
46
Charles River Laboratories
CRL
$14.2B
$535K 0.48%
4,955
+2,393
+93% +$246K
GILD icon
47
Gilead Sciences
GILD
$185B
$524K 0.47%
6,462
+3,206
+98% +$245K
MDCO
48
DELISTED
Medicines Co
MDCO
$519K 0.47%
14,000
– –
TECH icon
49
Bio-Techne
TECH
$11.4B
$516K 0.46%
17,072
+8,624
+102% +$256K
IQV icon
50
IQVIA
IQV
$43.2B
$515K 0.46%
5,413
+2,492
+85% +$231K
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2017 Portfolio in Review

As of Q3 2017, Opus Point Partners Management held 70 positions worth $111M, up 2.1% from $109M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Opus Point Partners Management deployed $4.8M of net new capital in Q3 2017, opening 3 new positions and adding to 23 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $140K trimmed.

  • Opus Point Partners Management's largest Q3 2017 buy was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.
  • Opus Point Partners Management added most to Ultragenyx Pharmaceutical in Q3 2017, an estimated $340K increase.
  • Opus Point Partners Management's biggest Q3 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $140K.
  • Opus Point Partners Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $613K.
  • Opus Point Partners Management's ten largest holdings make up 45% of its $111M portfolio in Q3 2017.
  • Opus Point Partners Management opened 3 new positions and closed 7 in Q3 2017.
  • Opus Point Partners Management's portfolio value rose 2.1% quarter-over-quarter to $111M.

Based on Opus Point Partners Management's 13F filing for Q3 2017, filed 14 Nov 2017.